Beata Lecka-Czernik

Summary

Affiliation: University of Toledo
Country: USA

Publications

  1. pmc β-catenin directly sequesters adipocytic and insulin sensitizing activities but not osteoblastic activity of PPARγ2 in marrow mesenchymal stem cells
    Sima Rahman
    Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America
    PLoS ONE 7:e51746. 2012
  2. pmc PPARgamma2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells
    K R Shockley
    The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA
    PPAR Res 2007:81219. 2007
  3. pmc Marrow fat metabolism is linked to the systemic energy metabolism
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, University of Toledo Health Sciences Campus, Toledo, OH 43614, USA
    Bone 50:534-9. 2012
  4. ncbi request reprint Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus
    Beata Lecka-Czernik
    University of Toledo, College of Medicine, Department of Orthopaedic Surgery, 3000 Arlington Avenue, Toledo, OH 43614, USA
    IDrugs 13:793-801. 2010
  5. ncbi request reprint Bone as a target of type 2 diabetes treatment
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, University of Toledo Medical Center, Center for Diabetes and Endocrine Research, Toledo, OH 43614, USA
    Curr Opin Investig Drugs 10:1085-90. 2009
  6. doi request reprint PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism
    Beata Lecka-Czernik
    Departments of Orthopaedic Surgery and Physiology and Pharmacology, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH, 43614, USA
    Curr Osteoporos Rep 8:84-90. 2010
  7. pmc Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, OH, 43614, USA
    Curr Osteoporos Rep 8:178-84. 2010
  8. pmc Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I
    Cheryl L Ackert-Bicknell
    The Jackson Laboratory, Bar Harbor, Maine 04609, USA
    Endocrinology 150:1330-40. 2009
  9. pmc Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton
    Sima Rahman
    Departments of Orthopaedic Surgery, University ofToledo Health Sciences Campus, Toledo, OH 43614, USA
    Endocrinology 154:2687-701. 2013
  10. ncbi request reprint A chromosomal inversion within a quantitative trait locus has a major effect on adipogenesis and osteoblastogenesis
    Cheryl L Ackert-Bicknell
    The Jackson Laboratory, Bar Harbor, ME 04609, USA
    Ann N Y Acad Sci 1116:291-305. 2007

Collaborators

Detail Information

Publications16

  1. pmc β-catenin directly sequesters adipocytic and insulin sensitizing activities but not osteoblastic activity of PPARγ2 in marrow mesenchymal stem cells
    Sima Rahman
    Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America
    PLoS ONE 7:e51746. 2012
    ..In conclusion, β-catenin and PPARγ2 are in cross-talk which results in sequestration of pro-adipocytic and insulin sensitizing activity. The anti-osteoblastic activity of PPARγ2 is independent of this interaction...
  2. pmc PPARgamma2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells
    K R Shockley
    The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA
    PPAR Res 2007:81219. 2007
    ..These observations may have important therapeutic consequences and indicate a need for more detailed studies of PPARgamma2 role in stem cell biology...
  3. pmc Marrow fat metabolism is linked to the systemic energy metabolism
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, University of Toledo Health Sciences Campus, Toledo, OH 43614, USA
    Bone 50:534-9. 2012
    ..These functions may include a role in bone energy maintenance and endocrine activities to serve osteogenesis during bone remodeling and bone healing...
  4. ncbi request reprint Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus
    Beata Lecka-Czernik
    University of Toledo, College of Medicine, Department of Orthopaedic Surgery, 3000 Arlington Avenue, Toledo, OH 43614, USA
    IDrugs 13:793-801. 2010
    ..A phase III clinical trial was also ongoing in patients with T2DM who had recently experienced a cardiac event...
  5. ncbi request reprint Bone as a target of type 2 diabetes treatment
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, University of Toledo Medical Center, Center for Diabetes and Endocrine Research, Toledo, OH 43614, USA
    Curr Opin Investig Drugs 10:1085-90. 2009
    ..In summary, bone is a target of certain antidiabetic therapies and, therefore, caution is necessary in the choice of treatment for patients who are at risk of skeletal complications...
  6. doi request reprint PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism
    Beata Lecka-Czernik
    Departments of Orthopaedic Surgery and Physiology and Pharmacology, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH, 43614, USA
    Curr Osteoporos Rep 8:84-90. 2010
    ..We also discuss the role of bone fat in modulation of bone marrow microenvironment and its possible contribution to the systemic regulation of energy metabolism...
  7. pmc Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, OH, 43614, USA
    Curr Osteoporos Rep 8:178-84. 2010
    ..We also suggest a possible orthopedic complication, not yet supported by clinical studies, of delayed fracture healing in T2DM patients on TZD therapy...
  8. pmc Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I
    Cheryl L Ackert-Bicknell
    The Jackson Laboratory, Bar Harbor, Maine 04609, USA
    Endocrinology 150:1330-40. 2009
    ..The divergent skeletal responses to rosiglitazone in this study suggest the existence of a strong genetic background effect...
  9. pmc Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton
    Sima Rahman
    Departments of Orthopaedic Surgery, University ofToledo Health Sciences Campus, Toledo, OH 43614, USA
    Endocrinology 154:2687-701. 2013
    ..Conversely, CM derived from cells overexpressing IGFBP2 or WNT10b restored osteoblastic activity in recipient cells. In conclusion, beige fat secretes endocrine/paracrine activity that is beneficial for the skeleton...
  10. ncbi request reprint A chromosomal inversion within a quantitative trait locus has a major effect on adipogenesis and osteoblastogenesis
    Cheryl L Ackert-Bicknell
    The Jackson Laboratory, Bar Harbor, ME 04609, USA
    Ann N Y Acad Sci 1116:291-305. 2007
    ..Rather, 6T demonstrates that disordered regulation of gene expression by genomic rearrangement can have a profound effect on a complex trait, such as BMD, and that genomic rearrangement can supersede the effects of various alleles...
  11. pmc PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells
    Keith R Shockley
    The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine 04609, USA
    J Cell Biochem 106:232-46. 2009
    ....
  12. doi request reprint Polycaprolactone nanofiber interspersed collagen type-I scaffold for bone regeneration: a unique injectable osteogenic scaffold
    Nuray Baylan
    Department of Bioengineering, College of Engineering, University of Toledo, Toledo, OH 43606, USA
    Biomed Mater 8:045011. 2013
    ....
  13. doi request reprint Peroxisome proliferator-activated receptor delta agonist attenuates nicotine suppression effect on human mesenchymal stem cell-derived osteogenesis and involves increased expression of heme oxygenase-1
    Dong Hyun Kim
    Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA
    J Bone Miner Metab 31:44-52. 2013
    ..This offers insight into both how nicotine affects bone remodeling and a therapeutic approach to prevent fracture and osteoporosis in smokers...
  14. pmc Skeletal aging and the adipocyte program: New insights from an "old" molecule
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, Toledo, Ohio, USA
    Cell Cycle 9:3648-54. 2010
    ..In this Extra View we discuss the interactive role of three molecules, PPARγ, nocturnin and IGF-I in regulating stem cell fate in the marrow and the potential implications of this network for understanding cellular aging...
  15. ncbi request reprint An overview of recent advances in designing orthopedic and craniofacial implants
    Venkata P Mantripragada
    Biomedical Engineering Program, The University of Toledo, Toledo, Ohio, 43614 5807
    J Biomed Mater Res A 101:3349-64. 2013
    ..Recent advances in orthobiologics are proving interesting as well. This paper thus deals with the latest improvements being made to the existing implant materials and includes new materials being introduced in the field of biomaterials...
  16. pmc Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass
    Vipula Kolli
    Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America Center for Diabetes and Endocrine Research, University of Toledo College of Medicine, Toledo, Ohio, United States of America
    PLoS ONE 9:e96323. 2014
    ..They also suggest a relationship between PPARγ fat "browning" activity and a lack of anti-osteoblastic activity. ..

Research Grants10

  1. PPAR gamma-2 expression in marrow stroma during aging
    Beata Lecka Czernik; Fiscal Year: 2001
    ..Such intervention may slow down or even prevent age-related bone loss. ..
  2. Bone loss with aging occurs due to increased PPAR-g activity in marrow stem cells
    Beata Lecka Czernik; Fiscal Year: 2009
    ..Completion of the above aims should enable us to determine the role of PPARg in this process and will allow designing therapeutic interventions that will selectively block PPARg anti-osteoblastic activity. ..
  3. Bone loss with aging occurs due to increased PPAR-g activity in marrow stem cells
    Beata Lecka Czernik; Fiscal Year: 2006
    ..Completion of the above aims should enable us to determine the role of PPARg in this process and will allow designing therapeutic interventions that will selectively block PPARg anti-osteoblastic activity. ..
  4. PPAR gamma-2 expression in marrow stroma during aging
    Beata Lecka Czernik; Fiscal Year: 2005
    ..Such intervention may slow down or even prevent age-related bone loss. ..
  5. PPAR gamma-2 expression in marrow stroma during aging
    Beata Lecka Czernik; Fiscal Year: 2004
    ..Such intervention may slow down or even prevent age-related bone loss. ..
  6. PPAR gamma-2 expression in marrow stroma during aging
    Beata Lecka Czernik; Fiscal Year: 2003
    ..Such intervention may slow down or even prevent age-related bone loss. ..
  7. Bone loss with aging occurs due to increased PPAR-g activity in marrow stem cells
    BEATA ANNA LECKA CZERNIK; Fiscal Year: 2010
    ..Completion of the above aims should enable us to determine the role of PPARg in this process and will allow designing therapeutic interventions that will selectively block PPARg anti-osteoblastic activity. ..
  8. PPAR gamma-2 expression in marrow stroma during aging
    Beata Lecka Czernik; Fiscal Year: 2002
    ..Such intervention may slow down or even prevent age-related bone loss. ..